Abstract
Background: The Duke Anticoagulation Satisfaction Scale (DASS) offers a method to measure the quality of life and satisfaction of patients taking oral anticoagulants. The study aimed to validate the Chinese version of the DASS in Chinese patients on anticoagulation therapy. Methods: The DASS was translated, back-translated, and transculturally adapted into the Chinese version and then administered to participants taking oral anticoagulants in a physician–pharmacist collaborative anticoagulation clinic at a tertiary teaching hospital from October 2019 to December 2020. Reliability was analyzed through Cronbach’s alpha (α) and split-half reliability. Confirmatory factor analysis was performed to test the structural validity of the scale. Exploratory factor analysis was performed for items in the scales using the varimax rotation method. Results: A total of 189 patients completed the Chinese version of the DASS. Four dimensions and 23 items were included, with Cronbach’s α values of 0.89, 0.81, 0.89, and 0.74 for limitations on physical activities, diet restrictions, hassles and burdens, and positive psychological effect, respectively. Cronbach’s α coefficient of whole scale was 0.91. The split-half reliability of this scale is 0.747 (>0.7). Conclusion: The Chinese version of the DASS indicated excellent reliability and validity, compared to the original version. It could provide a practical instrument for healthcare practitioners to evaluate satisfaction and quality of life for anticoagulated patients in China. The difference in quality of life between patients taking warfarin and novel oral anticoagulants (NOACs) needs to be further explored in future studies.
Highlights
Oral anticoagulants, including warfarin and novel oral anticoagulants (NOACs), are used to treat venous thromboembolism, such as pulmonary embolism and deep vein thrombosis, and prevent stroke in patients with atrial fibrillation (Keeling et al, 2011; Mueck et al, 2014; Cohen et al, 2015; Cohen et al, 2016; Witt et al, 2016; Bai et al, 2017)
Dissatisfaction with anticoagulation is associated with poor adherence, international normalized ratio (INR) control, and clinical outcomes (Perino et al, 2019)
To facilitate the evaluation of quality of life and address the gap of Duke Anticoagulation Satisfaction Scale (DASS) applied in Chinese, this study aimed to assess the reliability and validity of the Chinese version of the DASS among patients receiving oral anticoagulant therapy
Summary
Oral anticoagulants, including warfarin and novel oral anticoagulants (NOACs), are used to treat venous thromboembolism, such as pulmonary embolism and deep vein thrombosis, and prevent stroke in patients with atrial fibrillation (Keeling et al, 2011; Mueck et al, 2014; Cohen et al, 2015; Cohen et al, 2016; Witt et al, 2016; Bai et al, 2017). Common generic scales are widely used to measure healthrelated quality of life, including the EuroQol Five Dimensions Questionnaire (EQ-5D) (Balestroni and Bertolotti, 2012) and the MOS item short form health survey (SF-36) (Ware and Sherbourne, 1992). Their comprehensiveness hinders the deep understanding of patients on specific medications. The Duke Anticoagulation Satisfaction Scale (DASS) is specially developed and validated to measure the quality of life and satisfaction of patients taking oral anticoagulants (Samsa et al, 2004). The Duke Anticoagulation Satisfaction Scale (DASS) offers a method to measure the quality of life and satisfaction of patients taking oral anticoagulants. The study aimed to validate the Chinese version of the DASS in Chinese patients on anticoagulation therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
